Abstract 94P
Background
Immunotherapy combined with chemotherapy as neoadjuvant therapy has shown promising efficacy. Tislelizumab is an anti-PD-1 mAb approved in China for the treatment of first-line advanced squamous NSCLC in combination with chemotherapy. This study aimed to evaluate the efficacy of tislelizumab combined chemotherapy as neoadjuvant therapy in resectable stage IIA–IIIB squamous NSCLC in a real-world setting.
Methods
A retrospective analysis included patients (pts) with resectable IIA–IIIB (AJCC 8th) squamous NSCLC who received neoadjuvant tislelizumab combined with chemotherapy at Second Affiliated Hospital of Medical School of Zhejiang University between Apr 2020 and Oct 2022. The primary endpoints were major pathological response (MPR) rate and pathological complete response (PCR) rate; secondary endpoints included objective response rate (ORR) by RECIST1.1, down-staging rate and safety outcomes.
Results
60 pts were included with a median age of 55 (range 41–85) years, and 98% males. 56 pts were administrated with tislelizumab combined with nab-paclitaxel plus platinum-based chemotherapy, and other 4 pts chemotherapy regime was paclitaxel instead of nab-paclitaxel. All pts received 2–3 cycles neoadjuvant therapy. The MPR rate and PCR rate were 81.67%(95%CI:69.56,90.48) and 41.67%(95%CI:29.07,55.12) respectively. The ORR, and down-staging rate were 75%(95%CI:62.14,85.28), 38.3%(95%CI:26.07,51.79), As of 1 Oct 2022, the median follow-up time was 20 (range: 4–29) months, 7 pts experienced recurrence, and 5 of them are non-MPR. For the safety information, mild immune-related AEs such as rash and pneumonitis were experienced in this retrospective analysis.
Conclusions
This real-world retrospective study revealed that tislelizumab combined with (nab)-Paclitaxel and platinum-based chemotherapy is a promising option as neoadjuvant therapy for resectable stage IIA-IIIB squamous NSCLC.
Legal entity responsible for the study
The authors.
Funding
BeiGene (Beijing) Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.